Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Find the latest information on COVID-19, monkeypox, and the flu vaccine

Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma management Grossman, D. n., Kim, C. C., Hartman, R. I., Berry, E. n., Nelson, K. C., Okwundu, N. n., Curiel-Lewandrowski, C. n., Leachman, S. A., Swetter, S. M. 2019; 6 (4): MMT32

Abstract

Prognostic gene expression profiling (GEP) tests for cutaneous melanoma (CM) are not recommended in current guidelines outside of a clinical trial. However, their use is becoming more prevalent and some practitioners are using GEP tests to guide patient management. Thus, there is an urgent need to bridge this gap between test usage and clinical guideline recommendations by obtaining high-quality evidence to guide us toward best practice use of GEP testing in CM patients. We focus here on the opportunities and uncertainties associated with prognostic GEP testing in CM, review how GEP testing was incorporated into clinical care guidelines for uveal melanoma and breast cancer and discuss the role of clinical trials to determine best use in patients with CM.

View details for DOI 10.2217/mmt-2019-0016

View details for PubMedID 31871621

View details for PubMedCentralID PMC6920745